Topic Archives: A&W Revenue Royalties Income Fund (AW-UN.TO AWRRF)

Roger Conrad has been a well known fan of relatively stodgy income stocks for a long time, with his Canadian Edge and Utility Forecaster both ranking among the top income-focused newsletters according to Stock Gumshoe reviewers for most of the past several years. And today’s he’s teasing us with yet another somewhat unusual income investment, […]

Comments

  • Gr8Full!

    VistaGen Therapeutics Receives Notice of Allowance of U.S. Patent for Treatment of Osteoarthritis and Joint Injuries wit...

  • Avatar

    $AXSM UW Axsome announces recommendations to continue COAST-1, discontinue CREATE-1 trial Axsome Therapeutics an...

  • SoGiAm

    40 Biggest Movers From Wednesday 5:50 am ET November 24, 2017 (Benzinga) Print Gainers Cleantech Solutions Intern...

  • Avatar

    $ AXSM NP : (AXSM) More News 08-Nov-2017:07:00:00, Axsome Therapeutics Reports Third Quarter 2017 Financial R...

  • Avatar

    I too have chronic pain from Failed back surgeries x3, Fibromyalgia, Osteoarthritis thru my body and just diagnosed with...

  • Avatar

    My heart goes out to you. My hubby has a hard time seeing me in constant pain.Failed back syndrome, Fibromyalgia, Osteoa...

  • Avatar

    $PSDV - i'm still holding. It's long way to go though. they file NDA in dec/jan and take a year for approval and take 2-...

  • Avatar

    $PSDV. Sivida Q4 Revenue Rises Over Year Ago Levels as Loss Narrows - up 10% in Early After-Hours 4:06 PM ET, 09/11...

  • Dr. KSS MD PhD

    Lucrative deals struck with Alimera that keep cash flowing into PsiVida. Psi also has knee osteoarthritis program----...

  • Avatar

    The good DRKSS is correct. I had a large dog that was diagnosed with Osteoarthritis the only option I could find at the ...

  • Avatar

    Hi Gummies This is my first post after joining SG , have been following you guys for sometime .really grateful for the...

  • Avatar

    $AXSM The IDMC will also perform the planned interim analysis of the Phase 3 COAST-1 trial of AXS-02 in knee osteoarthri...

  • Avatar

    $AXSM news (small position) [APOLOGIES: having formatting problems today - everything is run together] ---- Q3 COAST-1...

  • Avatar

    Ben, I know you're wanting to know where things stand with $AXSM. This was posted on Biopharm Catalyst News a few da...

  • arch1

    My experience with Gasa was that it is less effective than a glass of cold water. My doc wants to put me on it for my os...

  • Avatar

    $AXSM New corporate slide deck released 8/17/17. AXS-02 interim analysis in Knee Osteoarthritis and Complex Regional ...

  • Avatar

    Here are my choices; $ARTH - This is a game changer and my biggest position $BSTG - I'm hoping long term that t...

  • SoGiAm

    $CARA np down ~27% in AH - $CARA TFW you can't even make the difference look bigger after changing the Y Axis https:...

  • Avatar

    Hello people. To help clarify my own thoughts I've tried to compile a list of coming catalysts for some of our favourite...

  • Avatar

    I first was exposed to the use of alpha hydroxyproline, a special amino acid found in gelatin, to help with osteoarthrit...

  • Avatar

    $No Ticker Another alternative to knee replacement for Osteoarthritis by $PSDV https://www.hss.edu/newsroom_hss-a...

  • Avatar

    $AXSM: Initial AXS-02 Phase 3 trial data readout expected in 4Q17. AXS-02 is in Phase 3 development with Fast Track stat...

  • SoGiAm

    $PARNF long competition - Galliprant® (grapiprant tablets) Now Available for Canine Osteoarthritis Elanco launches fir...

  • Avatar

    NSAID side effect study results are in! A ten year, 24,000 patient study at the Cleveland Clinic has addressed safety c...

  • Avatar

    Telcomonster, That's the way I read the SEC filing too. I'm not sure how soon the re-listing might occur. They are build...

  • Avatar

    I agree with you on Zydax and I'm willing to say it will be a block buster, and IIRC there are other drugs in the pipeli...

  • Michael Jorrrin (aka Doc Gumshoe)

    Many interesting comments, for which many thanks! You Gumshoe Denizens do an excellent job of answering each other, ta...

  • Avatar

    Yesterday at the end of the day - the last half hour - there was a huge buy on PARN. Could PARN be waking up finally? ...

  • Dr. KSS MD PhD

    Hi niizajim: Thanks for posting and bringing up Kitov $KTOV. For home gamers, this is an Israeli biotech that got a SPA ...

  • Avatar

    $PARN - barely long PARN reports 67% increase in 6 mth earnings. Sounds very good. New products coming to market so...

  • SoGiAm

    $PARN long - Parnell Pharmaceuticals Holdings Ltd Announces Financial Results for the Six-Month Period Ended June 30, 2...

  • JohnM

    I am long $ARLZ. I agree the Canadian drugs are me-too. They are deploying a new sales force this month to bring Fibric...

  • sogiam

    $ZYNE - http://zynerba.com/ Company Profile Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company foc...

  • Michael Jorrin (aka Doc Gumshoe)

    Many thanks for all the comments. Here are a few comments on the comments, which I hope will be helpful. To Rich B...

  • sogiam

    *Regulus Therapeutics Reports Interim Analysis of RG-101 Shows 97% Response at 8-Week Follow Up Flexion Therapeutics R...

  • Dr. KSS MD PhD

    Mark....specifically for the osteoarthritis drug? I'm curious. $PARN....

  • sogiam

    AXSM-Has the Gummune looked at this equity and science? Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutic...

  • Dr. KSS MD PhD

    I spoke to an old friend who is purchasing manager for a large veterinary clinic. She said Parnell isn't yet detailing Z...

  • Dr. KSS MD PhD

    Are any Gummerati still in Parnell ($PARN)? I am getting bad vibes about this stock. We should be hearing from the FDA a...

  • Gui_

    PETX - Aratana Therapeutics Files for First FDA Approval Aratana Therapeutics, Inc. (PETX) After Hours Trading $3....

  • Avatar

    KITOV http://finance.yahoo.com/news/kitov-pharmaceuticals-pivotal-phase-iii-120000858.html Kitov Pharm (KTOV) drug KIT...

  • Avatar

    After this Biotech downturn some that look very enticing and undervalued to me that we follow at these prices with good...

  • Avatar

    I like Larry's original instincts in that I am more comfortable with companies developing products with huge markets , a...

  • om sharma

    Dr. KSS, I am just curious how zynerba products pipeline works for hard to cure Epilepsy, Fragile X Syndrome and Osteo...

  • sogiam

    Parnell Pharmaceuticals Holdings Ltd Announces Positive Top-Line Pivotal Trial Results for Zydax(R), Disease-Modifying O...

  • Dr. KSS, MD PhD

    Jabber----I think it will work in post-herpetic neuralgia. But we won't know for a year. At most 100 patients in the EU ...

  • Avatar

    XENE/TEVA update on TV-45070 phase 2B study for Osteoarthritis. http://finance.yahoo.com/news/teva-xenon-tv-45070-phase...

  • sogiam

    FLXN-BURLINGTON, Mass., June 3, 2015 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that a...

  • Dr. KSS, MD PhD

    Parnell ($PARN) plans an 18 June webcast investor presentation at which time it will release data from Zydax phase III f...

  • Avatar

    Dr.KSS, A very timely article for me . Was invested in AMPIO but because of your concerns a long time ago about its pr...

  • DBMD

    Thanks for the keen knee article, CBYL itself sounds like some Gk reference or source of wisdom. I have often wondered w...

  • Avatar

    $XENE: Xenon Pharmaceuticals to Provide Business and Milestone Update at Jefferies 2015 Global Healthcare Conference ...

  • Dr Bonz

    Prolotherapy is not looked on favorably since there are very few good prospective randomized blinded studies that show t...

  • Avatar

    Thanks for your informative post, DG. It seems as though you did a lot of research before undergoing this procedure, wh...

  • Dr. KSS, MD PhD

    $PARN at one time faced some emerging competition in the animal osteoarthritis market from smaller rival Nexvet. Nexvet ...

  • Avatar

    Dr KSS, Pretty sure I am not HCV positive as the Army game me a huge amount of tests in 2011, when I retired last year...

  • Dr. KSS, MD PhD

    More evidence (as if it were needed) that acupuncture is total nonsense: Acupuncture for chronic knee pain: a randomi...

  • Avatar

    I keep hoping that one day arthritis will be better understood and treated. Sharon don't know if this something which w...

  • Avatar

    Same here Doc - they have even compounds on the backburner for rheumatoid arthritis and osteoarthritis, and autism. But...

  • om sharma

    Dr, KSS, Will you be writing any Article on Osteoarthritis sometime ? I have few Question - 1. New discovery, Succ...

  • Dr. KSS, MD PhD

    David B: I poked around some into Flexion. Its drug closest to market is a long-acting intra-articular steroid for kn...

  • Avatar

    JZ, Are you or your Canadian investment circles looking into Theralase (OTC:TLTFF & TLT on the TSX), ? SA has it as ...

  • Avatar

    Hey Gang: Here's the latest details on AMPE - FDA trials schedule, i had to save as pdf to share it with you. Hope all ...

  • Avatar

    Anika therapeutics gets approval this AM to treat Osteoarthritis. Stock up $15 to $49. No position. Delmar still cre...

  • Avatar

    I work in an industry for which prediction of life span is important. One of the characteristics of rheumatoid arthritis...

  • Avatar

    This is copied and an excerpt of longer testimony but directly on point: Let’s go back a sec to 2010. Many out ther...

  • Avatar

    As someone who eats only organic fruits and vegetables, I certainly agree that it is much safer to avoid eating chemical...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch